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DIABETES IS A CHRONIC CONDITION in which the pancreas does not produce enough insulin (Type 1 diabetes) or the body is unable to properly utilize insulin (Type 2 diabetes). It is estimated that the worldwide prevalence of diabetes in adults (20 to 79 yr of age) was 6.6% (285 million people) in 2010 and will increase to 7.8% (438 million people) by the year 2030 (23) . Subcutaneous (SC) insulin therapy is a common mode of diabetes treatment but can be burdened by complications (hypoglycemia, edema) and low patient compliance (32) . As such, considerable effort has been put forth to develop oral insulin formulations that can provide bioactive insulin in a noninvasive manner that poses minimal patient risk.
There are numerous barriers to the oral administration of insulin, including the physical barrier, the enzymatic barrier, and the instability of insulin in the gastrointestinal tract (16, 50) . The physical barrier refers to the mucus and viscous fluid (containing mucins, enzymes, electrolytes, and water) that line the epithelium of the small intestine, as well as the physical integrity of the intestinal epithelium attributable to tight junctions between cells. The enzymatic barrier refers to the presence of enzymes in the stomach (pepsin) and duodenum (trypsin, chymotrypsin, and carboxypeptidases) that act to break down proteins and peptides including insulin. The stability of insulin in the gastrointestinal tract is low because of large variations in pH during transit and degradation attributable to enzymatic activity. Combined, these factors contribute to a general lack of absorption of free insulin when administered orally; less than 2% of insulin is absorbed from the human small intestine into the systemic circulation (9) .
Numerous delivery systems that are based on nanoparticles have been evaluated for the oral administration of insulin. Such systems also may find utility in food-related applications of nanotechnology in situations where it may be desirable to encapsulate additives or nutrients to target them to specific areas of the gastrointestinal tract. Several recent review articles have nicely summarized the variety of nanotechnology-based strategies that have been used to encapsulate and deliver insulin orally (1, 16, 18, 32, 50) . The present review was undertaken to provide an update on the literature related to the efficacy and safety evaluations that have been conducted with nanoparticle-based oral delivery systems for insulin. A particular focus of this effort was on identifying studies that have determined the pharmacological availability of orally-delivered nanoparticle insulin formulations compared with that achieved by a standard SC dose of free insulin. Moreover, given the variety of nanoparticle formulations that have been evaluated and the general lack of knowledge of particular nanomaterial characteristics that may contribute to oral toxicity and risks associated with oral exposure to nanomaterials, an evaluation was undertaken of the toxicity and safety data that have been reported for nanoparticle-based formulations for the oral delivery of insulin.
MATERIALS AND METHODS

Identification of Relevant Literature
An electronic literature search was conducted to identify articles related to the oral administration of insulin via nanoparticle-mediated delivery systems. The U.S. National Library of Medicine's PubMed database (http://www.ncbi.nlm.nih.gov/pubmed) was utilized for this purpose. A search of the PubMed database was conducted on Sep To be considered further for inclusion in this review, articles were required to summarize studies in which unmodified insulin was administered orally to humans or experimental animals in a nanoscale formulation of one form or another. Articles were excluded from further consideration if they summarized studies that 1) evaluated a modified form of insulin (e.g., aspart-insulin), 2) employed only a nonoral route of administration (e.g., SC injection or direct injection into the ileum), or 3) did not provide any efficacy or safety data (e.g., only described absorption, distribution, or other pharmacokinetic parameters).
Identification of Information on Oral Excipient Exposure
Information pertaining to the existing use of the various formulation components that were identified in the reviewed studies was obtained from the following sources. The Handbook of Pharmaceutical Excipients (36) and the Physician's Desk Reference (http://www.pdrel.com/View/ Security/Login.aspx?ReturnUrlϭ%2fdefault.aspx) were first searched to determine whether the excipients that were identified as being used in the various published studies are present in approved oral drug formulations. Subsequently, to identify maximum amounts of the excipients that are present in approved oral capsule or tablet formulations, an electronic search was conducted of the Inactive Ingredient Database for Approved Drug Products that is maintained by the U.S. Food and Drug Administration (U.S. FDA) (http://www.accessdata.fda.gov/scripts/cder/iig/ index.cfm). In addition, to determine whether any of the excipients are considered generally recognized as safe (GRAS) for specific uses in food, searches were conducted of the U.S. FDA's Database of Select Committee on GRAS Substances (SCOGS) Reviews (http://www.accessdata.fda. gov/scripts/fcn/fcnNavigation.cfm?rptϭscogsListing&displayAllϭtrue#45) and of the U.S. FDA's GRAS Notice Inventory (http://www.accessdata.fda.gov/scripts/fcn/fcnNavigation.cfm?rptϭgrasListing). All of these searches were conducted on December 20, 2010.
Assessment of Nanomaterial Characterization
For each of the articles selected for inclusion, a determination was made of the completeness and reporting of the physicochemical characterization of the nanomaterials that were being assessed within the study. For this purpose, a "nanomaterial score" was derived based on the extent of nanomaterial characterization that was conducted and reported (3) . A given study received 1 point toward the nanomaterial score for each of the following 10 parameters that were reported (listed here in alphabetical order): agglomeration and/or aggregation, chemical composition, crystal structure/crystallinity, particle size/size distribution, purity, shape, surface area, surface charge, surface chemistry (including composition and reactivity), and whether any characterization was conducted in the relevant experimental medium. Thus the nanomaterial score for each study ranged from 0 (no characterization) to 10 (extensive characterization).
RESULTS
The literature search identified a total of 401 titles, all of which were subsequently reviewed. From these, numerous abstracts were selected and reviewed for relevance (i.e., to determine whether articles might contain information on efficacy and/or safety of nanoparticle-mediated oral delivery of insulin). A total of 68 abstracts were identified as containing information potentially relevant to the efficacy and/or safety of orally administered nanobased formulations of insulin in experimental animals or humans. These 68 articles were acquired and reviewed in full.
On the basis of the inclusion and exclusion criteria described above, a total of 30 articles were excluded from further consideration. The following reasons were cited for exclusion: oral administration was not assessed (17 studies); an insulin analog was used (4 studies); no efficacy or toxicity data were presented (3 studies); particles were not in the nanorange (2 studies); information on the nanoparticle carrier was lacking (2 studies); oral dose levels in units of IU/kg body wt were not provided (1 study); and oral dosing was accomplished by encapsulating nanoparticles in an "enteric-coated capsule" with no further details provided on the capsule (1 study). This review therefore summarizes data and findings from 38 primary research articles. Of the studies reported in these 38 articles, three were conducted in mice and 35 were conducted in rats. None of the studies were conducted in a nonrodent species.
The subsequent sections of this article provide summaries of the efficacy and toxicity data that were reported in the 38 primary research articles and an overview of the extent of nanomaterial physicochemical characterization that was reported in these articles. Efficacy data are presented separately based on whether or not an assessment was made of the pharmacological availability of the oral nanoparticle formulation vs. a standard SC dose of free insulin. The limited toxicity data that were reported in the 38 studies are summarized, as is an overview of current oral pharmaceutical and food uses of the components of the various nanoparticle formulations that were evaluated in the 38 studies. Nanomaterial characterization is summarized with reference to an established metric upon which such characterization can be scored (3) .
Efficacy Data
Each of the 38 studies that were included in this review evaluated some measure of efficacy of nanoparticle-mediated oral administration of insulin in mice or rats. The majority of studies utilized a single oral administration of the test formulation to healthy or diabetic animals and evaluated the effects on blood glucose levels for hours or days following dosing. The reported studies utilized human, bovine, and porcine insulin, and evaluations were conducted in diabetic mouse models and in healthy and diabetic rats. Several different nanoparticle-based formulations for the oral delivery of insulin have been evaluated. The majority of the nanocarrier components that have been tested are biocompatible and biodegradable substances such as chitosan, dextran, polyalkylcyanoacrylates, and solid lipid nanoparticles.
In many cases, a standard SC dose of free insulin was used as a comparator to evaluate the pharmacological availability of the oral formulation. These studies form the basis of this review and are summarized in Table 1 and in the next section. Information in Table 1 is presented in alphabetical order in terms of the primary nanoparticle components that were evaluated. As such, some studies appear in multiple places in were evaluated within them. Studies in which a standard SC dose of free insulin was not used as a comparator are not summarized in this review; a written and tabulated summary of these studies can be obtained upon request from the corresponding author.
Data from studies that evaluated pharmacological availability of oral nanoparticle insulin dosing relative to that of subcutaneous free insulin dosing. The studies summarized in this section compared the efficacy of oral dosing with insulinloaded nanoparticles to that resulting from a standard SC dose of free insulin. In each of these studies, the authors derived the pharmacological availability of the orally administered insulin by comparing its effect on blood glucose levels with that of a single SC dose of free insulin. A total of 17 studies reported on the pharmacological availability of the nanoparticle formulation(s) that were tested (6, 7, 10 -12, 17, 20, 29, 34, 38 -40, 44, 51, 53-55) . A summary of the pharmacological availability data from these studies is presented in Table 1 .
The data in Table 1 indicate a wide range of pharmacological availabilities for the various nanoparticle formulations that have been evaluated. More information on these results is presented in the following sections that are subdivided according to the main component(s) of the nanoparticle formulations that were evaluated.
CHITOSAN-BASED NANOPARTICLES. Cui et al. (12) prepared insulin-loaded nanoparticles from carboxylated chitosan and poly(methyl methacrylate) (PMMA) and evaluated their ability to reduce blood glucose levels in normal and diabetic rats. The carboxylated chitosan-PMMA nanoparticles were reported to be spherical, 200 to 300 nm in size, negatively charged (-potential ϭ Ϫ41 to Ϫ57 mV), and essentially homogeneous (polydispersity index of 0.014). The insulin-loaded nanoparticles had a reported diameter of 251 to 319 nm and were somewhat less negatively charged (-potential ϭ Ϫ22.0 to Ϫ26.4 mV). In normal rats, a single oral administration that provided insulin (type not specified) at a dose of 15, 25, 50, or 100 IU/kg body wt resulted in a decrease in blood glucose levels of ϳ20, 30, 30, and 40%, respectively, by 9 h postdosing. The reduced blood glucose levels were maintained through to 12 h postdosing (the last time point evaluated). Compared with a single SC insulin dose of 1 IU/kg body wt, the pharmacological availability of the 25 IU/kg body wt dose of insulin-loaded nanoparticles was 9.7% (pharmacological availabilities at the other dose levels were not reported).
Elsayed et al. (17) evaluated a chitosan-based nanoparticle system to deliver bovine insulin to diabetic rats. In this study, chitosan-insulin polyelectrolyte complexes were prepared and suspended in an oily phase composed of oleic acid, plurol oleique (polyglyceryl-6-dioleate), and labrasol (PEG 8 caprylic/ capric glycerides). The chitosan-insulin polyelectrolyte complexes were positively charged (-potential ϭ 29.97 mV), and the resulting nanoparticles in the oily phase were spherical and 108 nm in size. A single oral administration that provided insulin at a dose of 50 IU/kg body wt to fasted diabetic rats resulted in a decrease in blood glucose of ϳ40% at 8 h postdosing. The animals were fed 12 h postdosing, and blood glucose returned to baseline values by 24 h postdosing. Compared with the reduction in blood glucose that was achieved with a single SC dose of insulin of 1 IU/kg body wt, the oral nanoparticle formulation had a pharmacological availability of 7%. When animals were fed throughout the study as opposed to only beginning 12 h postdosing, the pharmacological availability was found to be much less, at 2.57%. This indicates that the presence of food significantly decreased the efficacy of the nanoparticle formulation, likely attributable to the processes of food digestion and prolonged gastric residence time, both of which increase the likelihood of insulin degradation in the stomach.
Chitosan-based nanoparticles containing 1% poloxamer 188 were evaluated by Pan et al. (29) . Nanoparticles containing insulin (type not specified) were 289.3 Ϯ 31.2 nm in size and positively charged (-potential ϭ 32.56 mV) and were administered to fasting diabetic rats at doses providing insulin at 7, 14, or 21 IU/kg body wt. Maximum reductions in blood glucose in each group of ϳ25, 40, and 60% were observed at 10 h postdosing, and levels were maintained well below baseline through to ϳ24 h postdosing. After this time, glucose levels rose but remained below baseline until 36 h postdosing (the last time point assessed). Compared with the hypoglycemic effect resulting from a SC dose of free insulin of 1 IU/kg body wt, the pharmacological availability of the insulin-loaded nanoparticles following oral dosing were calculated to be 14.0, 15.6, and 15.3% for the 7, 14, and 21 IU/kg body wt dose levels, respectively. Sarmento and colleagues (38) prepared insulin-containing nanoparticles made with dextran sulfate and chitosan in a weight ratio of 1.5:1 or 1:1.5. In both cases, human insulin was entrapped in the nanoparticles, which were administered to fasted diabetic rats. Nanoparticles with a 1.5:1 ratio of dextran sulfate and chitosan were 527 nm in size, spherical, and negatively charged (-potential ϭ Ϫ20.6 mV), whereas those with a 1:1.5 ratio also were spherical but were larger in size (1,577 nm) and positively charged (-potential ϭ 24.0 mV). Administration of the 1.5:1 ratio nanoparticles at a dose of 50 or 100 IU/kg body wt resulted in decreased blood glucose levels that were maintained for up to 24 h (the last time point evaluated). Relative to a SC dose of free insulin of 2.5 IU/kg body wt, the pharmacological availabilities of the insulin-loaded nanoparticles at the 50 and 100 IU/kg body wt dose levels were 5.6 and 3.4%, respectively. A 50 IU/kg body wt dose of the 1:1.5 ratio nanoparticles also resulted in a significant decrease in blood glucose (a maximum decrease of ϳ30% at 6 h that was maintained through to 24 h postdosing), but the pharmacological availability of this formulation was not reported. The authors concluded that both formulations are viable candidates for oral delivery of biologically active insulin.
The same research group also evaluated insulin-loaded nanoparticles that were prepared with chitosan and sodium alginate (40) . In this study, nanoparticles with an alginate: chitosan mass ratio of 4.3:1 were prepared in the presence of human insulin. The nanoparticles were 748 nm in size and were slightly negatively charged (-potential ϭ Ϫ5.6 mV). Fasted diabetic rats were administered the nanoparticles to provide an insulin dose of 25, 50, or 100 IU/kg body wt. The maximum decrease in blood glucose for the low-, mid-, and high-dose groups was 24.3% (8 h), 42.2% (14 h), and 44.8% (14 h), respectively. The decrease in blood glucose in all three groups was maintained for up to 24 h postdosing (the last time point evaluated). Compared with the effects of a SC dose of free insulin of 2.5 IU/kg body wt, the 25, 50, and 100 IU/kg body wt doses of insulin-loaded nanoparticles displayed pharmacological availabilities of 7.1, 6.8, and 3.4%, respectively.
Thus the glucose-lowering effect was saturated at the 50 IU/kg body wt dose level. Serum insulin was measured in animals in the 50 and 100 IU/kg body wt groups with maximum levels detected 2 h postdosing in both groups. These data support insulin-loaded alginate:chitosan nanoparticles as potential oral delivery vehicles for insulin.
DEXTRAN-BASED NANOPARTICLES. Chalasani et al. (6) evaluated dextran nanoparticles conjugated to vitamin B 12 as a carrier system to deliver insulin. The intent of their study was to exploit vitamin B 12 uptake via the intrinsic factor-vitamin B 12 receptor pathway as a means to increase gastrointestinal uptake of insulin. Dextran nanoparticles conjugated with vitamin B 12 were loaded with insulin (2, 3, or 4% wt/wt) and evaluated in vitro for drug release and proteolytic degradation properties. In vivo evaluation was conducted in diabetic rats that were given a single oral dose of one of the nanoparticle formulations to provide an insulin dose of 20 IU/kg body wt. A comparative SC dose of insulin of 0.4 IU/kg body wt was evaluated in a separate group of animals. Of the different formulations that were assessed, the one in which nanoparticles were prepared with dextran with a molecular weight of 70,000 g/mol and with 3% insulin wt/wt provided the greatest reduction in blood glucose levels. These nanoparticles were reported to be 192 nm in average size and to have a polydispersity index of 0.81 (i.e., to be very heterogeneous in size); no information on shape or charge was provided. The hypoglycemic effect of these insulin nanoparticles was characterized by an ϳ70% reduction in blood glucose at 5 h postdosing, a return to baseline 8 -10 h postdosing, and a subsequent 70% reduction 24 h postdosing. The pharmacological availability of this formulation was reported to be 26.5%. Similar nanoparticles prepared without conjugated vitamin B 12 were reported to have a pharmacological availability of 10.3%, supporting the feasibility of targeting the intrinsic factor-vitamin B 12 receptor pathway to increase the bioavailability of oral insulin.
A subsequent study by the same authors evaluated the effects of different degrees of cross linking and of various vitamin B 12 derivatives on the efficacy of human insulin delivered by dextran-vitamin B 12 -conjugated nanoparticles (7) . Insulin conjugated to dextran-vitamin B 12 nanoparticles that had the least amount of cross linking were found to be the most effective at lowering blood glucose levels. An amino hexyl vitamin B 12 derivative via carbamate linkage, dosed to deliver insulin at 20 IU/kg body wt, was reported to have the greatest hypoglycemic effect in diabetic rats with a pharmacological availability of 29.4% relative to that of a single SC insulin dose of 0.4 IU/kg body wt. Only the size of these nanoparticles was reported (256 nm, with a polydispersity index of 0.83); information on shape and charge was not provided. Importantly, human insulin was detected in the blood for up to 54 h postdosing, confirming prolonged delivery of the protein via the nanoparticles to the circulation.
Woitiski and colleagues (51) evaluated a multilayered nanoparticle system in which sodium alginate and dextran sulfate were nucleated around calcium, bound to poloxamer 188, stabilized by chitosan, and coated with albumin (51) . Human insulin was entrapped in these nanoparticles, which were reported to be spherical, 396 nm in average size but heterogeneous (polydispersity index ϭ 0.6), and negatively charged (-potential ϭ Ϫ38.2 mV). Administration to fasted diabetic rats at an insulin dose of 50 IU/kg body wt was reported to be associated with a pharmacological availability of 10.7% relative to that of a SC dose of free insulin of 1 IU/kg body wt. The maximum reduction in blood glucose was ϳ62% and was attained 12 h postdosing; maintenance of blood glucose at ϳ50% of the predose level was observed 24 h postdosing. Maximum serum insulin levels were achieved 8 h postdose, and the 24-h area under the curve for insulin was greater than that observed for the SC dose of free insulin. Administration of the 50 IU/kg body wt dose 8 h before an oral glucose challenge (dose not reported) resulted in a significantly lesser increase in blood glucose than was observed in animals administered the same dose of free insulin. Cumulatively, data from this study indicate that the multilayered nanoparticle system exerted an effective and sustained hypoglycemic effect in diabetic rats.
A study by Reis et al. (34) evaluated nanospheres that were mucoadhesive, biodegradable, biocompatible, and acid protected. The insulin-containing core of the nanospheres was made from sodium alginate and dextran sulfate. These were then coated with a layer of chitosan, BSA, and PEG 4000. The authors reported that 90% of the nanoparticles loaded with human insulin had diameters less than 1,842 nm. Moreover, the nanoparticles were negatively charged (-potential ϭ Ϫ7 mV) but changed to positively charged (21 mV) upon incubation for 2 h with pepsin, suggestive of favorable adhesion/absorption in the intestines. Administration of a single dose of 25, 50, or 100 IU/kg body wt to fasted diabetic rats dose dependently decreased blood glucose over the course of 14 h. The maximum decrease was observed at the 14-h time point and was 44, 55, and 76%, respectively. Compared with a SC dose of free insulin of 4 IU/kg body wt, the 25, 50, or 100 IU/kg body wt doses of the insulin-loaded nanoparticles had calculated pharmacological availabilities of 42, 21, and 10%, respectively. Administration of nanoparticles that lacked PEG 4000 and BSA in the coating layer did not result in a hypoglycemic effect, supporting the importance of these components in stabilizing the nanoparticles in the gastrointestinal tract. A 50 IU/kg body wt oral dose of nanoparticles given 10 h before an oral glucose challenge (2 g/kg body wt) reduced the peak glycemia in diabetic rats by nearly 50%. In addition, compared with predosing levels, blood insulin levels measured for up to 8 h postdosing were four-to sixfold higher in diabetic rats that were dosed with nanoparticles at 50 IU/kg body wt, confirming delivery of insulin to the blood. Importantly, this study was the only one identified in which insulin-loaded nanoparticles were repeatedly administered to diabetic rats over the course of several days. Diabetic rats administered a daily dose of 50 IU/kg body wt for 4 consecutive days demonstrated significant reductions in 24-h measurements of water intake (42%), urine volume (47%), and proteinuria (67%), indicating an improvement in metabolic status in these animals as a result of the nanoparticle-mediated delivery of insulin.
SOLID LIPID NANOPARTICLES. Sarmento et al. (39) evaluated human insulin-containing nanoparticles that were prepared from cetyl palmitate and that contained poloxamer 407 as a surfactant. The insulin-loaded solid lipid nanoparticles were spherical in shape, 361 nm in size, and slightly negatively charged (-potential ϭ Ϫ3.4 mV). A single oral administration to fasted diabetic rats decreased blood glucose levels fairly rapidly; levels were decreased by Ͼ20% 4 h postdosing and reached a nadir of 27% at 14 h postdosing. Relative to a SC dose of free insulin at 2.5 IU/kg body wt, the pharmacological availability of the insulin-loaded nanoparticles was calculated to be 5.1%. The authors concluded that these solid lipid nanoparticles may represent a suitable carrier system for oral insulin delivery.
Zhang et al. (54) prepared solid lipid nanoparticles based on a combination of stearic acid, lecithin, and poloxamer 188. They also examined the influence of modifying the nanoparticles by incorporating wheat germ agglutinin-N-glutaryl-phosphatidylethanolamine in an attempt to increase binding to cell surface glycans in the gastrointestinal tract. The unmodified solid lipid nanoparticles were spherical, 64.5 nm in size, and had a negative surface charge (-potential ϭ Ϫ46.27 mV). The modified nanoparticles were spherical, slightly larger (75.3 nm in size), and less negatively charged (-potential ϭ Ϫ13.11 mV). The type of insulin that was incorporated into these nanoparticles was not specified. When administered to normal rats that were not fasted, a dose of the unmodified nanoparticles equivalent to an insulin dose of 50 IU/kg body wt decreased blood glucose by ϳ70% at 1 h postdosing; levels remained decreased for ϳ6 h and then returned to baseline. The same dose of insulin provided by the modified nanoparticles resulted in a maximum decrease of blood glucose of ϳ45% at 3 h postdosing that also lasted for ϳ6 h before returning to baseline. Relative to a SC dose of free insulin of 2 IU/kg body wt, the pharmacological availability of the unmodified and modified nanoparticles was 4.46 and 6.08%, respectively. These data reveal promising hypoglycemic effects of wheat germ agglutinin-modified solid lipid nanoparticles in normally fed rats.
The influence of incorporating a cell-penetrating peptide on the efficacy of insulin-loaded solid lipid nanoparticles was investigated by Zhang et al. (55) . These investigators prepared solid lipid nanoparticles from stearic acid, soybean phospholipids, and poloxamer 188 and included octaarginine (R8) as a nonspecific cell penetration enhancer. Porcine insulin-loaded solid lipid nanoparticles were spherical, 126 nm in size, and negatively charged (-potential ϭ Ϫ35.41 mV). Incorporation of R8 into the nanoparticles resulted in spherical particles that were slightly larger (151 nm in size) and positively charged (-potential ϭ 32.65 mV). When administered to fasted normal rats, insulin-loaded nanoparticles (20 IU/kg body wt) reduced blood glucose by 43% at 4 h postdosing and maintained levels below baseline for 12 h. A comparable dose of nanoparticles containing R8 reduced blood glucose by 64% at 3 h postdosing and likewise maintained levels below baseline for 12 h. Relative to SC insulin at 1 IU/kg body wt, the pharmacological availability of the normal and R8-containing nanoparticles was 5.66 and 10.39%, respectively, indicative of an enhanced efficacy as a result of incorporating the cell-penetrating peptide into the nanoparticle formulation.
Yang and colleagues (53) studied three different types of solid lipid nanoparticles (53) . In this study, solid lipid nanoparticles were prepared from cetyl palmitate, glyceryl tripalmitate, or glyceryl palmitostearate in combination with lecithin and Solutol HS15 (polyoxyl 15 hydroxystearate). Insulin (type not specified) was loaded into the nanoparticles, and the resulting sizes and surface charges were reported: cetyl palmitate, ϳ550 nm and Ϫ6 mV; glyceryl tripalmitate, ϳ450 nm and Ϫ9 mV; and glyceryl palmitostearate, ϳ300 nm and Ϫ12 mV. All insulin-loaded solid lipid nanoparticles were spherical in shape. When given at a dose of 50 IU/kg body wt to fasted diabetic rats, blood glucose was only nominally decreased in all three treatment groups. The maximum decrease in the cetyl palmitate, glyceryl tripalmitate, or glyceryl palmitostearate nanoparticle groups was 15, 20, and 25%, respectively, whereas the pharmacological availability relative to a SC dose of 2.5 IU/kg body wt was 2.92, 3.44, and 4.53%, respectively. The authors concluded that glyceryl palmitostearate represented the most promising lipid material for solid lipid nanoparticle delivery of insulin.
POLYALKYLCYANOACRYLATE-BASED NANOPARTICLES. Hou et al. (20) prepared polybutylcyanoacrylate nanoparticles containing porcine insulin and tested them in diabetic rats when delivered in a soybean oil medium or in water. The nanoparticles were spherical in shape and had average sizes of 78 nm immediately after polymerization and of 67 nm when dispersed in the oily medium. When stored in the oily medium for 1 yr, the particles retained their shape and size, and the release profile for insulin was found to be comparable to prestorage values. Administration of the nanoparticles in oily medium to diabetic rats (at an insulin dose of 50 IU/kg body wt) resulted in a large and prolonged decrease in blood glucose; the maximum decrease was ϳ57% at 24 h postdosing, and decreased levels were maintained for up to 120 h. Nanoparticles dispersed in water decreased blood glucose by a maximum 42% (at 48 h postdosing) and maintained decreased levels for 96 h. Thus the oily medium resulted in increased efficacy. Compared with a SC dose of free insulin of 2 IU/kg body wt, the nanoparticles suspended in oily medium and in water had pharmacological availabilities of 22.4% and 15.5%, respectively. Importantly, the authors noted that food intake and changes of body weight in animals administered the insulinloaded nanoparticles (in oily medium or water) did not differ from those of control animals administered insulin-free nanoparticles suspended in the oily medium.
PLGA-BASED NANOPARTICLES. On the basis of comparison with a SC insulin dose of 1 IU/kg body wt, Cui et al. (10) reported a pharmacological availability of 7.7% for a single oral dose of a poly(lactic-co-glycolic acid) (PLGA)-based insulin nanoparticle system that delivered insulin at a dose of 20 IU/kg body wt. In this study, the hydrophobicity of porcine insulin was increased by preparing it in a mixture with soybean phosphatidylcholine before incorporation into nanoparticles prepared from PLGA and polyvinyl alcohol (PVA). The resultant nanoparticles were relatively homogeneous with a size range of 146 to 201 nm (10th to 90th percentile), were spherical in shape, and were negatively charged (-potential ϭ Ϫ17.8 mV). A single oral dose in diabetic rats resulted in a decrease in the blood glucose level to ϳ50% of baseline by 12 h postdosing, and this was maintained until 24 h postdosing (the last time point of observation).
These authors subsequently evaluated the influence of adding hydroxypropylmethylcellulose phthalate (or HP55) to the PLGA-PVA nanoparticles on their efficacy in diabetic rats (11) . According to the authors, HP55 is a pH-sensitive cellulose coating that is designed for use in enteric coatings for various capsules and tablets. In this study, nanoparticles made with PLGA in the absence of HP55 or in the presence of HP55 (PLGA:HP55 in a 1:2 wt/wt ratio) were loaded with porcine insulin. The reported sizes of these spherical particles were 150 Ϯ 17 nm and 169 Ϯ 16 nm, respectively; information on surface charge was not provided. A single oral administration to diabetic rats that provided an insulin dose of 20 IU/kg body wt was found to result in a maximum decrease in blood glucose of 40% and 60% for the PLGA and PLGA-HP55 nanoparticles, respectively, and the corresponding pharmacological availability relative to a single SC insulin dose of 1 IU/kg body wt was 3.68% and 6.27%. With both formulations, measurable serum insulin levels were attained for up to 12 h postdosing, and sustained decreases in blood glucose were observed for up to 24 h postdosing (the last time point evaluated). The increased activity of insulin delivered by the PLGA ϩ HP55 nanoparticles was attributed to improved stability of these nanoparticles in the acidic environment of the stomach.
A more recent study by this research group determined the potential for nanoparticles prepared from PLGA and PVA to deliver an insulin-sodium oleate complex to diabetic rats (44) . In this study, a porcine insulin-sodium oleate complex was encapsulated in PLGA-PVA nanoparticles that were spherical, 161 nm in size, homogeneous (polydispersity index ϭ 0.082), and negatively charged (-potential ϭ Ϫ33.4 mV). A single dose to fasted diabetic rats of 20 IU/kg body wt reduced blood glucose by 76% at 12 h postdosing, and this decreased level was maintained through to 24 h postdosing. The pharmacological availability relative to a SC dose of free insulin of 1 IU/kg body wt was reported to be 11.5%. In a separate group of diabetic rats, the insulin-loaded nanoparticles were administered 1 h before an oral glucose challenge (2 g/kg body wt), and effects on glycemia were observed. Compared with animals administered saline, animals administered the insulinloaded nanoparticles had a lower peak blood glucose level and a 47% lower area under the curve for blood glucose over the 4-h postdosing period. Thus these nanoparticles were effective at maintaining lowered blood glucose in diabetic rats and at improving the glycemic response to oral glucose challenge.
Data from studies that evaluated hypoglycemic effects of oral nanoparticle insulin dosing. A total of 23 studies reported data from evaluations that did not compare oral dosing with insulin-loaded nanoparticles to a standard SC dose of free insulin (2, 5, 7, 12-15, 19, 24 -28, 30, 31, 33, 35, 37, 41, 42, 47, 49, 52) . These studies are not summarized in this review; a written and tabulated summary of these studies can be obtained from the corresponding author upon request. Two of these studies, however, also contained elements in which an evaluation of pharmacological availability was conducted (7, 12) ; these data are summarized in the preceding section. The results of these 23 studies collectively indicate that the various nanoparticle formulations are, to varying degrees, efficacious at decreasing blood glucose levels in normal and/or diabetic animals.
Safety and Toxicity Data
Data reported in the reviewed studies. Limited data have been reported that pertain to the safety and toxicity of the nanoparticle formulations that were evaluated in the studies summarized in this review. In the vast majority of the studies that were identified, a single dose of the nanoparticle formulation was administered and animals were monitored for up to a few days postdosing for blood glucose and occasionally for blood insulin levels. Notably, one study evaluated repeat-dose effects following a 14-day dosing regimen in normal mice, and another study evaluated once weekly dosing for 8 mo in nonobese diabetic (NOD) mice. The toxicity data that have been reported in the 38 studies included in this review are summarized below.
IN VITRO DATA. In their study of carboxylated chitosan-PMMA nanoparticles, Cui et al. (12) conducted a hemolysis assay in which up to 300 l of a 1% solution of the nanoparticles (not loaded with insulin) were incubated with an erythrocyte suspension (the source of the erythrocytes was not reported) for 1 h at 37°C. No increase in hemolysis was observed in the presence of the nanoparticles, suggestive of suitable blood compatibility.
IN VIVO DATA. Cui et al. (12) studied the biocompatibility of carboxylated chitosan-PMMA nanoparticles in the ileum of normal rats. In an in situ preparation, 0.5 ml of a 1% solution of the nanoparticle formulation (not loaded with insulin) was injected into the ileum and incubated in a 10-cm segment for 1 h. The ileal loop was then flushed with PBS, and the activity of lactate dehydrogenase (LDH) was determined in the eluent. Compared with control ileal loops incubated with PBS, no increase in LDH activity was observed following incubation with the insulin-loaded nanoparticles, whereas a significant increase was observed with the positive control sodium tauroglycocholate. Thus epithelial integrity and cellular tight junctions in the ileum remained intact in the presence of the nanoparticles.
In a study of polybutylcyanoacrylate nanoparticles containing porcine insulin, Hou et al. (20) reported that administration of a single dose in a soybean oil medium or in water did not result in altered food intake or body weight changes in diabetic rats compared with rats administered an oral dose of free insulin as a control. No other safety or toxicity data were reported.
In their evaluation of insulin-containing nanoparticles made from a core of sodium alginate and dextran sulfate that was coated with a layer of chitosan, PEG 4000, and BSA, Reis et al. (34) administered to diabetic rats a daily dose of 50 IU/kg body wt for 4 consecutive days. Significant reductions in 24-h measurements of water intake (42%), urine volume (47%), and proteinuria (67%) were observed, indicating an improvement in metabolic status in these animals. No specific safety or toxicity data were reported in this study, but the authors indicated that additional metabolic studies were to be performed to characterize metabolic and toxicological effects during continuous and prolonged oral administration.
Sonaje et al. (41) evaluated nanoparticles prepared from chitosan and poly(␥-glutamic acid) in the presence of magnesium sulfate and sodium tripolyphosphate (TPP). The empty nanoparticles (not loaded with insulin) were administered to male and female ICR mice at a dose level of 100 mg/kg body wt/day for 14 days. Control mice were left untreated. In-life parameters that were assessed included clinical signs and body weight. Following the last dose, animals were killed and blood samples prepared for clinical chemistry and hematology assessments. Internal organs were observed grossly, and the liver and kidney were processed and evaluated histologically. No statistical differences from the control values were noted in any of the measured outcomes, and no evidence of gross or histological abnormalities was reported, suggesting that the nanoparticles were well tolerated over the course of a 14-day repeat-dose regimen. It is unclear why the authors evaluated the repeat-dose toxicity of the empty nanoparticle formulation in mice when they evaluated the efficacy of the insulin-loaded nanoparticles in diabetic rats.
Finally, Sai et al. (37) prepared human insulin-containing nanoparticles (average 280 nm in size) from polyisobutylcyanoacrylate, miglyol, and poloxamer 188 and administered them to NOD mice once weekly for 8 mo. The weekly dose was 100 IU/kg body wt. Although gross and histopathological assessments of gastrointestinal or other tissues were not conducted, no overt abnormalities were reported to result from this prolonged repeat-dose regimen.
Regulatory status of the various nanoparticle components. As summarized above, data or findings related to the safety and toxicity of the nanobased insulin formulations were presented or discussed in only 6 of the 38 articles that were included in this review. Given the limited information that is available, no conclusions can be made regarding the toxicity profiles of the different formulations and their components.
Several of the substances that have been evaluated as components of the various nanoparticle formulations that were identified in this review are known to be used in oral formulations of various drug products that are currently on the market. As such, searches were conducted of authoritative sources to identify information pertaining to the use of the tested components in approved oral formulations. For this purpose, the Handbook of Pharmaceutical Excipients (36), the Physician's Desk Reference, the U.S. FDA Inactive Ingredient Database for Approved Drug Products, the U.S. FDA Database of SCOGS Reviews, and the U.S. FDA's GRAS Notice Inventory were searched. The results of these searches can be obtained from the authors upon request.
Many of the components of the various nanoparticle formulations are included in approved oral drug products as indicated by their listing in the Physician's Desk Reference and the U.S. FDA Inactive Ingredient Database. Such is the case for sodium alginate, Eudragit L100 -55, hydroxypropylmethylcellulose phthalate (hypromellose phthalate), soya lecithin, magnesium sulfate, poloxamers 188 and 407, polyvinyl alcohol, and stearic acid. Others were identified in the U.S. FDA Inactive Ingredient Database but not in the Physician's Desk Reference (e.g., Eudragit RS, gold, PEG 4000, and sodium tripolyphosphate) or vice versa (e.g., dextran 70, dextran sulfate, and Eudragit S100). The listing of a component as being present as an inactive ingredient in one or more approved oral drug products does not constitute endorsement of that component as being safe for oral administration in general. This is because the level of inactive ingredients in different drug products varies according to the desired technical effect and because the dosing regimens of different drug products differ considerably (e.g., once daily vs. once weekly) such that the exposure pattern to a given inactive ingredient in one oral drug product may differ greatly from the exposure pattern for the same inactive ingredient in another oral drug product. The same is true for the U.S. FDA GRAS status of a given component, as GRAS status relates to specific uses of an ingredient in certain types of food and not to general consumption of that component in the diet.
It is noteworthy that many of the substances that were evaluated as components of the nanoparticle formulations were not identified as being present as inactive ingredients in approved drug products. Examples of these include chitosan, poly(lactic acid), PLGA, the polyalkylcyanoacrylate substances [e.g., polybutylcyanoacrylate, polyisobutylcyanoacrylate, polyethylcyanoacrylate, and poly(methyl methacrylate)], and Solutol HS15. This does not imply that they are not safe for oral use but rather indicates that they simply are not components of currently approved drug products.
As is the case for the development of any new drug product, inclusion of a given component as an inactive ingredient in an oral insulin product intended for human use needs to be justified technically in terms of the necessity for its inclusion in the intended drug formulation and scientifically in terms of its demonstrated safety in a standard series of toxicology studies that are conducted with the intended drug formulation.
Nanomaterial Physicochemical Characterization
The extent of physicochemical characterization of the nanomaterial formulations varied among the studies (Table 2) . Calculated nanomaterial scores ranged from 2 to 8. All 38 studies reported information on the chemical composition of the studied nanoparticles and data pertaining to size/size distribution. Most of the studies reported information pertinent to the shape of the nanoparticles (29 studies), whether agglomeration/aggregation was observed (25 studies), and surface charge characteristics (24 studies). Although difficult to ascertain in many instances, approximately half of the studies (20) appeared to have conducted some aspect of the physicochemical characterization in the relevant experimental medium (i.e., in the oral dosing solution). Notably absent from all of the studies was information on the purity and the relative surface area of the nanoparticles that were evaluated.
DISCUSSION
This review was undertaken to identify and summarize efficacy and toxicity data for nanoparticle-based systems for the oral delivery of insulin. A search of the PubMed database of the U.S. National Library of Medicine identified 38 articles that summarized studies that utilized unmodified insulin (human, bovine, or porcine) that was incorporated into nanoparticle-based formulations and assessed for efficacy following oral administration to normal or diabetic mice or rats.
In 17 of the 38 studies that were identified, a comparator group of animals was administered a SC dose of free insulin to allow for derivation of the pharmacological availability of insulin from the oral dosing formulation. A variety of substances was used to prepare the insulin-loaded nanoparticles that were evaluated in these 17 studies. The reported pharmacological availability in diabetic rats ranged from a low of 2.92% for solid lipid nanoparticles prepared from cetyl palmitate in combination with lecithin and Solutol HS15 (53) to a high of 42% for a multilayered nanoparticle composed of an insulin-containing core made from sodium alginate and dextran sulfate that was coated with a layer of chitosan, PEG 4000, and BSA (34) .
The majority of the components of the tested nanoparticle formulations are biocompatible and biodegradable. Chitosan is a biocompatible polymer that acts as an absorption enhancer via increasing paracellular permeability across mucosal epithelia (45) . Chitosan-based nanoparticles were evaluated in 12 studies (5, 12, 17, 25, 26, 29, 30, 35, 38, 40 -42) . The highest insulin pharmacological availabilities for chitosan-based nanoparticles were 9.7% and 15.6% in the studies reported by Cui et al. (12) and Pan et al. (29), respectively. Nanoparticles designed around the biodegradable polymer PLGA have demonstrated pharmacological availabilities of 11.5% (44) , whereas nanoparticles based on PLGA in combination with PVA were shown to have a pharmacological availability of 7.7% (10) . The relatively high pharmacological availabilities that have been reported with these and other biocompatible and biodegradable polymers are promising with respect to the potential for oral delivery of bioactive insulin in carriers that may pose little toxicological concern.
Recent studies by Chalasani and colleagues (6, 7) have exploited the intrinsic factor-vitamin B 12 receptor-mediated uptake pathway for vitamin B 12 to increase uptake of insulin following oral dosing. In these studies, dextran-based nanoparticles were conjugated to vitamin B 12 or a vitamin B 12 derivative and evaluated in diabetic rats. Nanoparticles loaded with 3% insulin and conjugated to vitamin B 12 provided a pharmacological availability of 26.5%, whereas nonconjugated nanoparticles had a pharmacological availability of 10.3%, supporting the utility of targeting the vitamin B 12 uptake pathway to deliver insulin (6) . Nanoparticles conjugated to an amino hexyl vitamin B 12 derivative via carbamate linkage were found to have a slightly better pharmacological availability of 29.4%, indicating that additional modifications can improve on the already effective vitamin B 12 -mediated delivery of bioavailable insulin to the gastrointestinal tract (7) .
The hypoglycemic efficacy that has been demonstrated for the various nanoparticle-based insulin formulations suggests that such formulations might be useful for the oral delivery of peptide or protein drug candidates for other disease conditions. The possibility also exists that such formulations could be used for the delivery of nutrients, additives, and other components in various food matrices (8, 22) . Examples could include the incorporation of a fat-soluble vitamin into an aqueous beverage or a water-soluble mineral into a fatty food item. Like the formulations that are being evaluated for oral insulin delivery, food-related nanoparticles and nanoparticle-based formula- Table 2 . Summary of nanomaterial characterization tions will need to be assessed for their oral safety before inclusion in food items. At the present time, however, information available in the published literature on the oral safety of food-related nanomaterials is lacking in terms of both quantity and quality (4) .
Similar to the case for food-related nanomaterials, very little toxicological data were reported in the studies on oral insulin delivery that were summarized in this review. Of the 38 studies that were identified, only six provided information relevant to the safety profile of the nanoparticle formulations that were tested. Of these, only one study provided data from what might be considered as standard toxicology testing parameters. In the study by Sonaje et al. (41) that evaluated nanoparticles prepared from chitosan and poly(␥-glutamic acid) in the presence of magnesium sulfate and TPP, in-life parameters (clinical signs and body weight) were assessed and terminal assessments included evaluation of blood samples for clinical chemistry and hematology, gross observation of internal organs, and histopathological assessment of the liver and kidney. No statistical differences from the control values were noted in any of the measured outcomes, and no evidence of gross or histological abnormalities was reported. These results suggest that the nanoparticles were well tolerated over the course of a 14-day repeat-dose regimen although it is noted that these toxicity evaluations were conducted in mice, whereas the efficacy aspect of the study was conducted in diabetic rats. The reason for using different species in these examinations was not provided (41) .
Although not considered standard toxicology protocols, some of the other methods that were utilized in the insulin studies reviewed here may be applicable to toxicity testing of other nanomaterials, including food-related nanomaterials. For example, the in situ ileal loop preparation utilized by Cui et al. (12) could be used as a screening method to examine direct effects of high concentrations of nanomaterials on intestinal tissues. The results of such an evaluation could inform on the design of subsequent in vivo studies in terms of vehicle, dose, and other experimental parameters.
It is clear that assessment of safety aspects of oral insulin dosing via nanoparticle-mediated systems has not received as much attention as has the assessment of efficacy. This is not surprising, given that formal toxicology testing is not expected to be initiated until a suitable nanoparticle formulation for the oral delivery of insulin has been identified and demonstrated to be effective in relevant animal models. Moreover, it is not anticipated that academic-type institutions (such as those from which the literature reviewed in this article originated) would conduct formal toxicology testing, but rather that such studies would be sponsored and/or conducted by biotechnology or pharmaceutical companies involved in the development of oral insulin therapies. This is especially true given the necessity for testing to be conducted in two mammalian species (one nonrodent) (21) and in accordance with Good Laboratory Practice regulations. In this regard, it is possible (but unknown to the authors) that some of the nanoparticle-based systems summarized in this review are presently undergoing toxicology evaluation with the goal of reaching human clinical trials, or that such trials may be underway. A large number of clinical trials were retrieved from the clinical trials registry of the U.S. National Library of Medicine (www.clinicaltrials.gov; accessed December 22, 2010) when a search was conducted using the terms "oral AND insulin", although it is unclear how many of these pertain to nanoparticle-based delivery systems.
Physicochemical characterization of nanomaterials that are evaluated in efficacy and toxicology studies is extremely important. A lack of adequate physicochemical characterization places a limit on the value and significance of the results of a given study and makes it difficult, if not impossible, to compare studies and identify parameters that might influence efficacy and/or safety (3, 43, 48) . With regard to physicochemical characterization of the nanomaterial formulations that were evaluated in the studies summarized here, it is noted that all 38 studies reported information on the chemical composition and the size/size distribution of the nanomaterials that were evaluated. To examine whether size alone influenced the ability of the various nanoparticle formulations to deliver bioavailable insulin, we compared the reported pharmacological availabilities of orally delivered insulin with the reported sizes of the insulin-containing nanoparticles that were tested in diabetic animals. For this comparison, we considered a total of 18 pharmacological availabilities (range: 2.92-29.4%) that were reported in 12 studies in which an average particle size was reported (range: 67-748 nm). Other pharmacological availability values were reported in studies conducted with diabetic animals but were for nanoparticle sizes within a given range and without a reported average size (10, 34) . From this evaluation, regression analysis revealed a very weak trend related to increased pharmacological availability with smaller particle size; the calculated r 2 value was 0.178. An analysis of the influence of particle size within particular categories of nanoparticle type (dextran-based, PLGA-based, etc.) could not be conducted because of the low numbers of particles (Յ4) of each type that were evaluated in diabetic animals. Thus, perhaps not surprisingly, size alone does not appear to significantly influence the ability of a nanoparticle to deliver via the oral route pharmacologically active insulin to the circulation. The influence of other parameters (e.g., shape, surface area, surface charge) on the delivery of pharmacologically active insulin to diabetic animals could not be determined because of a lack of available physicochemical data.
With regard to other physicochemical parameters, only 20 (approximately half) of the studies reported physicochemical characterization data that were generated from evaluations conducted in the dosing formulation (i.e., the most relevant medium), and none reported the relative surface area or information related to the purity of the nanomaterials. It is recognized that it often is difficult to define the purity of an engineered nanomaterial (46) . For example, it is not clear how this should be done for nanomaterials that may be composed of multiple entities, have a distribution profile for its primary particle size, have a surface coating, and aggregate in the relevant experimental medium. In such cases it is unclear how purity (and deviation from the stated purity) would best be described. Nonetheless, for the purpose of developing new drugs or food ingredients, it would be expected that purity information be provided, including data on levels of known impurities, carryover solvents, etc. In many of the articles summarized here, the purities of some of the source materials were reported, but no information was provided with regard to potential carryover of impurities or contamination of the final tested formulations. In the absence of such information, it would not be possible to investigate causality due to potential impurities or contaminants should subsequent studies reveal unexpected adverse effects at different dose levels or following repeated oral dosing.
Nanoparticles may be absorbed from the gastrointestinal tract by at least three different means: endocytosis by M-cells located in Peyer's patches, endocytosis by normal enterocytes, and via paracellular transport mechanisms. In all cases, penetration of the mucosal barrier is required, and this is influenced by various properties of nanomaterials that include, among others, size, surface charge, and surface chemistry. The various nanomaterial carriers that were evaluated in the studies that are summarized in this review covered a range of sizes and surface charges and were composed of a variety of constituent substances and coatings. Although no obvious relationship between any given physicochemical parameter and the absorption of pharmacologically available insulin could be determined, some aspects of the reviewed studies are worth further mention. In particular, it is interesting to note that the negative charge of the mucosal barrier would suggest that nanoparticle carriers with positive surface charges would fare better at interacting with and penetrating the barrier and offer a greater opportunity for absorption. This did not appear to be the general case in the studies reviewed here, at least for the few that evaluated pharmacological availability and reported data on surface charge. That being said, the nanoparticle carrier that provided the greatest pharmacological availability of 42% had one of the highest reported surface charges (21 mV following in vitro incubation with pepsin), suggestive of favorable adhesion/absorption in the intestines (34) . Other approaches taken in an attempt to improve insulin absorption met with varying levels of success. These included coating insulin-containing nanoparticles with pH-sensitive material (11) and conjugating them with vitamin B 12 and derivatives (6, 7) .
In summary, numerous articles that summarize various nanoparticle-based systems for the oral delivery of insulin were identified in the literature. The association of insulin with nanoparticle formulations designed to protect insulin from the harsh environment of the stomach and enhance its uptake in the ileum has been demonstrated to result in varying degrees of hypoglycemia in normal and diabetic animal models. Physicochemical characterization of the evaluated nanoparticle formulations was not always adequate, and future reports on studies in this area would benefit from the inclusion of more of these data so that better determinations may be made of parameters that might influence the efficacy and safety of a given formulation. To date, the most effective nanoparticle-based formulations in terms of pharmacological availability have been based on complex multilayered nanoparticles that are mucoadhesive, biodegradable, biocompatible, and acid-protected (34) and on nanoparticles designed to take advantage of the vitamin B 12 uptake pathway (6, 7) . Continued investigation, optimization, and safety testing of these and other formulations is anticipated to result in effective new oral therapies for the treatment of diabetes. Insights also may be gained into the use of nanoparticle-based formulations for peptide-and proteinbased oral treatment of other diseases and for food-related purposes.
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